Screener
MapLight Therapeutics, Inc. MPLT Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by MapLight Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: MapLight Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:25 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224129
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | $53,684 | $19,787 |
| General and administrative | 10,819 | 3,756 |
| Total operating expenses | 64,503 | 23,543 |
| Loss from operations | (64,503) | (23,543) |
| Other income, net: | ||
| Interest income | 2,472 | 811 |
| Other income, net | 1,363 | 392 |
| Net loss | $(60,668) | $(22,340) |
Item 1. Financial Statements.
FAQ
- What is MapLight Therapeutics, Inc.'s operating income?
- MapLight Therapeutics, Inc. (MPLT) reported operating income of -$64.5M in Q1 2026.
- How has MapLight Therapeutics, Inc.'s operating income changed year-over-year?
- MapLight Therapeutics, Inc.'s operating income decreased by 174.0% year-over-year, from -$23.54M to -$64.5M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about MapLight Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude